Ignite Creation Date:
2024-05-05 @ 10:50 PM
Last Modification Date:
2024-10-26 @ 10:25 AM
Study NCT ID:
NCT01199419
Status:
COMPLETED
Last Update Posted:
2014-07-18
First Post:
2010-09-09
Brief Title:
Cost-effectiveness of PCI With Taxus vs CABG - 5 Years FUP
Sponsor:
Medical University of Vienna
Organization:
Medical University of Vienna
Study Overview
Official Title:
Cost-effectiveness of Percutaneous Coronary Intervention With TAXUS Stents in Patients With Multivessel Coronary Artery Disease Compared With Aortocoronary Bypass Surgery 5 Years After Intervention
Status:
COMPLETED
Status Verified Date:
2014-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of the present study is to analyze the cost-effectiveness of percutaneous coronary intervention PCI using TAXUS stents compared to the costs of coronary artery bypass surgery CABG in patients with multivessel coronary artery disease CAD in the first 5 years and then 10 years after intervention Multivessel PCI or CABG was performed in 114 or 93 patients respectively Clinical outcomes in terms of incidence of acute myocardial infarction AMI all-cause death target vessel revascularization TVR and stroke resource use and costs are analyzed prospectively over a 5 and 10-year follow-up FUP period Overall costs consist of the baseline costs of the index procedure PCI or CABG clinical and angiographic procedure-related treatments during the entire FUP The primary endpoint is cost-effectiveness and clinical effectiveness defined as the reduction of the composite of major adverse cardiac and cerebrovascular events MACCE
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None